Maravai Lifesciences (MRVI) Investors Who Suffered Losses Encouraged to Contact Cohen Milstein
Rhea-AI Summary
Maravai LifeSciences (NASDAQ:MRVI) faces a securities class action lawsuit filed in the U.S. District Court for the Southern District of California. The lawsuit covers investors who purchased shares between August 7, 2024, and February 24, 2025.
The complaint alleges that Maravai and senior executives made false and misleading statements regarding:
- Financial controls and revenue recognition policies
- Improper revenue recording in fiscal 2024
- Overstated goodwill valuation
- Misrepresented financial condition and growth prospects
On February 25, 2025, Maravai announced delays in its earnings release and annual report due to revenue recognition concerns and a potential non-cash impairment charge. The stock subsequently dropped 21.7%. Affected investors have until May 5, 2025, to file for lead plaintiff status in the case.
Positive
- None.
Negative
- Alleged ineffective internal controls over financial reporting
- Improper revenue recognition in fiscal 2024
- Overstated goodwill valuation affecting financial health
- 21.7% stock price decline following disclosure
- Delayed earnings release and annual report
News Market Reaction – MRVI
In the trading session that priced this news, MRVI declined 1.23%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WASHINGTON, DC / ACCESS Newswire / March 19, 2025 / Cohen Milstein Sellers & Toll PLLC advises investors who purchased shares of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI) between August 7, 2024, and February 24, 2025 (the "Class Period") and suffered losses to contact the firm regarding a pending securities class action lawsuit.
To discuss your legal options, click here to connect with a Cohen Milstein team member or contact Partner Molly Bowen at mbowen@cohenmilstein.com.
CASE BACKGROUND:
Maravai is a biotechnology company that provides specialized products supporting drug development, diagnostics, and vaccine research. A complaint filed in the U.S. District Court for the Southern District of California alleges that the Company and certain senior executives made false and misleading statements about its financial controls, revenue recognition policies, and goodwill valuation, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The lawsuit alleges that, throughout the Class Period, Defendants failed to disclose that:
Maravai lacked effective internal controls over financial reporting, particularly in revenue recognition.
The Company improperly recorded revenue from certain transactions in fiscal 2024.
Maravai's goodwill valuation was overstated, misleading investors about its financial health.
Defendants misrepresented the Company's financial condition and growth prospects, creating an inflated perception of stability.
On February 25, 2025, Maravai announced a delay in its earnings release and annual report due to revenue recognition concerns and a potential non-cash impairment charge. Following this disclosure, the Company's stock price fell approximately
NEXT STEPS:
Investors who purchased MRVI shares during the Class Period and suffered substantial losses may be eligible to serve as lead plaintiff in this case. The deadline to file for lead plaintiff status is May 5, 2025. Investors are not required to serve as lead plaintiff to participate in any potential recovery.
ABOUT COHEN MILSTEIN:
Cohen Milstein Sellers & Toll PLLC is a national leader in securities litigation, with more than 100 attorneys across eight offices and a strong track record of fighting for investors. The firm has recovered billions of dollars on behalf of shareholders, including
For more information, visit www.cohenmilstein.com.
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION:
Molly Bowen, Esq.
Licensed in DC, Florida, and Ohio
Cohen Milstein Sellers & Toll PLLC
1100 New York Avenue, N.W., Fifth Floor
Washington, D.C. 20005
Telephone: (888) 240-0775 or (202) 408-4600
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com
# # #
SOURCE: Cohen Milstein Sellers & Toll PLLC
View the original press release on ACCESS Newswire